Table 2. Overlap Propensity Score–Weighted Characteristics and SARS-CoV-2 Test Positivity Among ACEI and ARB Usage Groups in All SARS-CoV-2 Tested Patients.
| Characteristic | All tested patients, %a | |||||
|---|---|---|---|---|---|---|
| ACEI | ARB | ACEI/ARB | ||||
| Yes | No | Yes | No | Yes | No | |
| Count, No. | 1322 | 17 150 | 982 | 17 490 | 2285 | 16 187 |
| Age, y | 62 | 62 | 65 | 65 | 62 | 62 |
| Male | 51 | 51 | 44 | 44 | 47 | 47 |
| Diabetes | 45 | 45 | 48 | 48 | 43 | 43 |
| CAD | 28 | 28 | 33 | 33 | 29 | 29 |
| Hypertension | 93 | 93 | 95 | 95 | 93 | 93 |
| COPD | 22 | 22 | 25 | 25 | 23 | 23 |
| HF | 25 | 25 | 30 | 30 | 26 | 26 |
| Tested positive | 8.6 | 9.5 | 10.0 | 9.3 | 9.1 | 9.4 |
| OR (95% CI) | 0.89 (0.72-1.10) | 1.09 (0.87-1.37) | 0.97 (0.81-1.15) | |||
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HF, heart failure; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Reported is either the overlap propensity score–weighted mean or proportion for each group.